The market correctly sees biology's potential but often misunderstands its timeline. Even with AI, biology is fundamentally harder and slower than software. Daniel Fero warns this mismatch in "tempo" expectations leads to over-funding hype cycles while under-funding foundational companies that are simply moving at the pace required for rigorous biological R&D.

Recent large financing rounds, like Soli's $200M Series C and Parabillus's $305M Series F, are predominantly for companies with proprietary discovery platforms rather than single-asset biotechs. This indicates investor confidence in technologies that can generate a pipeline of multiple future therapies, valuing repeatable innovation over individual drug candidates.

In a market favoring asset-centric biotech, Springtide VC remains focused on platform companies. This countercyclical strategy mitigates the binary risk of single-asset failure and allows for multiple "shots on goal" and diverse business models, such as partnerships or becoming a drug developer.

Top-tier venture capital firms are developing internal platforms with such demonstrable results and strong reputations that founders choose them over competitors offering higher valuations, seeking access to their unique support ecosystem.

The dominant biotech VC model incentivizes startups to act like real estate developers: build an asset to a certain stage (e.g., early clinical data) and then sell it to a large pharmaceutical company. This focus on short-term exits discourages the long-term, ambitious company-building required for revolutionary platforms.

The prevailing biotech model is shifting from an asset-centric approach to one focused on creating a "learning system." The most successful future companies will be those with a repeatable engine for discovery and validation that can consistently generate new insights and a diversified pipeline of assets.

For a platform company with wide-ranging technology, the key early struggle is focusing. It is critical to prioritize a single program to generate near-term data and change the cost of capital before realizing the platform's full potential.

The venture creation strategy for platform biotechs isn't about finding one blockbuster drug. It's a binary bet: either the underlying scientific platform is sound and can repeatedly generate many medicines, or the entire concept fails. There is no middle ground of succeeding with just one product from the platform.

Antonov highlights a core conflict: VCs want tangible drug assets for monetization, but solving complex problems like aging requires building broad computational platforms. This focus on near-term assets starves the development of fundamental, long-term biological models.